New insights into the mechanisms underlying vascular and cardiac effects of urocortin.

abstract：:Obesity and Gestational Diabetes Mellitus (GDM) are the most frequent pathologies affecting mothers and offspring during pregnancy. Both conditions have shown a sustained increase in their prevalence in recent years, and they worsen the outcome of pregnancy and the long-term health of mothers. Obesity increases the ri...

journal_title：Current vascular pharmacology

authors： Poblete JA,Olmos P

更新日期：2021-01-01 00:00:00

abstract：:Platelet activation induces rapid thrombus formation at a ruptured atherosclerotic plaque leading to acute vessel occlusion and a fatal or non-fatal cardiovascular event. More recent evidence suggests that activated platelets play an additional central role during the initiation of atherosclerosis, essentially facilit...

journal_title：Current vascular pharmacology

authors： Schäfer A,Bauersachs J

更新日期：2008-01-01 00:00:00

abstract：:Biomarkers are used in medicine to facilitate diagnosis, assess risk, direct therapy and determine efficacy of treatment. Sensitivity and specificity are essential in order for a biomarker to be useful. Brain natriuretic peptide (BNP) and C-reactive protein (CRP) are considered biomarkers of cardiovascular disease. Ho...

journal_title：Current vascular pharmacology

authors： Miller VM,Redfield MM,McConnell JP

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Vitamin D is a fat soluble vitamin involved in calcium and bone metabolism; recently its deficiency has been related to cardiovascular disease. In cardiac tissue, vitamin D suppresses metalloproteinases (MMPs) expression, enzymes directly associated with vulnerable plaque. OBJECTIVE:To investigate whether t...

journal_title：Current vascular pharmacology

authors： Machulsky NF,Barchuk M,Gagliardi J,Gonzalez D,Lombardo M,Escudero AG,Gigena G,Blanco F,Schreier L,Fabre B,Berg G

更新日期：2018-01-01 00:00:00

abstract：:High-mobility group box-1 (HMGB1) is a nuclear protein that acts as a cytokine when released into the extracellular milieu by necrotic and inflammatory cells, and is involved in inflammatory responses and tissue repair. This protein is released passively during cellular necrosis by almost all cells that have a nucleus...

journal_title：Current vascular pharmacology

authors： Biscetti F,Ghirlanda G,Flex A

更新日期：2011-11-01 00:00:00

abstract：:In the last decade there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VA) and Sudden Cardiac Death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally ...

journal_title：Current vascular pharmacology

authors： El-Sherif N,Pedalino R,Himel H 4th

更新日期：2009-07-01 00:00:00

abstract：:In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages ...

journal_title：Current vascular pharmacology

authors： Roumeliotis S,Roumeliotis A,Gorny X,Mertens PR

更新日期：2021-01-01 00:00:00

abstract：:The incidence of cardiovascular disease is low in healthy premenopausal women and increases with age especially after the menopause; this difference has been attributed to the loss of endogenous estrogen. Atherosclerosis is a chronic inflammatory condition of the vascular wall that may result in an acute clinical even...

journal_title：Current vascular pharmacology

authors： Bechlioulis A,Naka KK,Calis KA,Makrigiannakis A,Michalis L,Kalantaridou SN

更新日期：2010-03-01 00:00:00

abstract：BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...

journal_title：Current vascular pharmacology

authors： Rubboli A,Patti G

更新日期：2018-01-01 00:00:00

abstract：:Platelet aggregation induced by stirring of a platelet suspension after activation by the exogenous addition of stimulants, such as ADP, epinephrine and thrombin, has long been used as a platelet function test, and for the screening of antiplatelet agents. Since platelet aggregation has been demonstrated to be mediate...

journal_title：Current vascular pharmacology

authors： Goto S

更新日期：2004-01-01 00:00:00

abstract：:Aldosterone, a steroid hormone with mineralocorticoid activity, is far more than merely a salt-and-water hormone. Aldosterone has a number of non-classical, mineralocorticoid receptor (MR)-mediated actions, including tissue remodeling, modulation of vascular tone and stimulating inflammation and fibrosis, which may fu...

journal_title：Current vascular pharmacology

authors： Waanders F,de Vries LV,van Goor H,Hillebrands JL,Laverman GD,Bakker SJ,Navis G

更新日期：2011-09-01 00:00:00

abstract：:Oxidative stress has been linked to the origin and progression of cardiovascular diseases. Nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase is a multi-component, NADPH-dependent enzyme that generates superoxide anion in the presence of molecular oxygen. The enzyme has been identified and chara...

journal_title：Current vascular pharmacology

authors： Yu J,Weïwer M,Linhardt RJ,Dordick JS

更新日期：2008-07-01 00:00:00

abstract：:Atherosclerosis (also known as arteriosclerotic vascular disease) is a chronic inflammatory disease of the arterial wall, characterized by the formation of lipid-laden lesions. The activation of endothelial cells at atherosclerotic lesion-prone sites in the arterial tree results in the up-regulation of cell adhesion m...

journal_title：Current vascular pharmacology

authors： Araldi E,Chamorro-Jorganes A,van Solingen C,Fernández-Hernando C,Suárez Y

更新日期：2013-05-13 00:00:00

abstract：:Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...

journal_title：Current vascular pharmacology

authors： Dandel M,Hetzer R

更新日期：2010-09-01 00:00:00

abstract：:The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been under...

journal_title：Current vascular pharmacology

authors： Sharma V,McNeill JH

更新日期：2006-10-01 00:00:00

abstract：:We evaluated the effects of the glycosaminoglycan sulodexide (SDX; antithrombotic/profibrinolytic drug) on the activity and release of matrix metalloproteinases (MMPs) in human blood. This was a prospective non-randomized study, analyzing by zymography and ELISA the in vitro effects of SDX on pro-enzyme, complexed, an...

journal_title：Current vascular pharmacology

authors： Mannello F,Medda V,Ligi D,Raffetto JD

更新日期：2013-05-01 00:00:00

abstract：:Both endothelin(ET)-1 and oxidative stress have been the subjects of intense investigation within the cardiovascular field over the past decade and a half, yet little is known about the precise relationship between these important modulators of vascular function. There is a firm evidence that ET-1 can stimulate the pr...

journal_title：Current vascular pharmacology

authors： Pollock DM,Pollock JS

更新日期：2005-10-01 00:00:00

abstract：BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, dat...

journal_title：Current vascular pharmacology

authors： Imprialos K,Stavropoulos K,Bouloukou S,Kerpiniotis G,Karagiannis A,Doumas M

更新日期：2018-01-01 00:00:00

abstract：:Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resi...

journal_title：Current vascular pharmacology

authors： Breen DM,Giacca A

更新日期：2011-05-01 00:00:00

abstract：: ...

journal_title：Current vascular pharmacology

authors： Guerrero Orriach JL,Ramirez-Fernandez A

更新日期：2019-01-01 00:00:00

abstract：:Epidemiological evidence supports a reduced prevalence of Thoracic Aortic Aneurysm (TAA) and Abdominal Aortic Aneurysm (AAA) in patients with Diabetes (DM). The mechanisms underlying this negative association are unknown. Some studies support that hyperglycemia has effects on the Extracellular Matrix (ECM), resulting ...

journal_title：Current vascular pharmacology

authors： Krizhanovskii C,Franco-Cereceda A

更新日期：2019-01-01 00:00:00

abstract：:Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulat...

journal_title：Current vascular pharmacology

authors： Filippatos TD,Randeva HS,Derdemezis CS,Elisaf MS,Mikhailidis DP

更新日期：2010-01-01 00:00:00

abstract：:Matrix metalloproteinases (MMP) comprise a family of at least 25 zinc-dependent endopeptidases that play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after stroke, the dysregulation of MMPs has been described to increase acute neurovascular disruption and cerebral ...

journal_title：Current vascular pharmacology

authors： Lenglet S,Montecucco F,Mach F

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, having numerous indications. However, despite their therapeutic role, they are associated with serious cardiovascular (CV) adverse events. Objectives-Methods: This review comprising recent observational studies and metaanalyses over the past few...

journal_title：Current vascular pharmacology

authors： Kontogiorgis C,Valikeserlis I,Hadjipavlou-Litina D,Nena E,Constantinidis TC

更新日期：2016-01-01 00:00:00

abstract：:A considerable amount of data supports a 1.8-7.4-fold increased mortality associated with Cushing's syndrome (CS). This is attributed to a high occurrence of several cardiovascular disease (CVD) risk factors in CS [e.g. adiposity, arterial hypertension (AHT), dyslipidaemia and type 2 diabetes mellitus (T2DM)]. Therefo...

journal_title：Current vascular pharmacology

authors： Koracevic G,Stojkovic M,Lovic D,Pavlovic M,Kostic T,Kutlesic M,Micic S,Koracevic M,Djordjevic M

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:The primary objective of this study was to evaluate the impact of polypharmacy on primary and secondary adherence to evidence-based medication (EBM) and to measure factors associated with non-adherence among patients who underwent percutaneous coronary intervention (PCI). METHODS:We conducted a retrospectiv...

journal_title：Current vascular pharmacology

authors： Mohammed S,Arabi A,El-Menyar A,Abdulkarim S,AlJundi A,Alqahtani A,Arafa S,Al Suwaidi J

更新日期：2016-01-01 00:00:00

abstract：:Hypercoagulability is widely associated with sepsis, inflammation, diabetes, cancers, aging, and many pathological conditions, resulting in life-threatening disseminated intravascular coagulation (DIC), venous thrombosis, thromboembolism, cardiovascular complications, or even deadly multiple organ failure. Relieving c...

journal_title：Current vascular pharmacology

authors： Chu AJ

更新日期：2004-07-01 00:00:00

abstract：:The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease ...

journal_title：Current vascular pharmacology

authors： Athyros VG,Tziomalos K,Karagiannis A,Mikhailidis DP

更新日期：2009-07-01 00:00:00

abstract：:Preeclampsia (PE), gestational diabetes mellitus (GDM), and maternal supraphysiological hypercholesterolaemia (MSPH) are pregnancy-related conditions that cause metabolic disruptions leading to alterations of the mother, fetus and neonate health. These syndromes result in fetoplacental vascular dysfunction, where nitr...

journal_title：Current vascular pharmacology

authors： Leiva A,Fuenzalida B,Barros E,Sobrevia B,Salsoso R,Sáez T,Villalobos R,Silva L,Chiarello I,Toledo F,Gutiérrez J,Sanhueza C,Pardo F,Sobrevia L

更新日期：2016-01-01 00:00:00

abstract：:In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis fac...

journal_title：Current vascular pharmacology

authors： Kułdo JM,Ogawara KI,Werner N,Asgeirsdóttir SA,Kamps JA,Kok RJ,Molema G

更新日期：2005-01-01 00:00:00